• DoseID members, Bluesight and Sandoz, have agreed to launch RFID-tagged injectable medicines
• Two NDCs of Sandoz RFID-tagged medicines will be available in October 2020, with several more available through Q1 2021
• The RFID-tagged medicines are registered into the cloud-based Registry at the site of production and can be scanned in downstream KitCheck scanning stations in hospitals to ensure efficient restocking, patient safety, and inventory optimization

October 01, 2020 04:05 PM Eastern Daylight Time

WASHINGTON–(BUSINESS WIRE)–Bluesight, the market leader in software solutions for item-level visibility in the pharmaceutical space, in collaboration with Sandoz, a Novartis division, and global leader in generic pharmaceuticals and biosimilars, is pleased to announce that two Radio Frequency Identification (RFID)-tagged injectable generic Sandoz products will be available in United States hospitals in October 2020.

The first two medicines include Anectine 200 mg/10mL and Rocuronium 50mg/5mL and 10mg/5mL. Several more Sandoz medicines are expected to be made available pre-tagged with DoseID compliant RFID tags for KitCheck hospital partners through early 2021.

Both Sandoz and Bluesight are members of the newly formed industry consortium, DoseID, that certifies interoperable and high performing RFID technology in the healthcare space. Medications labeled with RFID tags at the manufacturer level ensures that there is item-level visibility of drug products throughout their dynamic lifecycle. This means better patient safety, optimized inventory for hospitals, cost savings, and dramatically increased workflow simplicity and efficiency.

RFID tags, in combination with the Registry, store information for each dose, including expiration date, lot number, NDC, and refrigeration date, so restocking, inventory management, and managing shortages and recalls is as seamless as possible. COVID-19 has continued to shine a light on the importance of item-level inventory management in the hospital, with KitCheck customers well poised to deal with the difficulty inventory challenges the pandemic has caused.

“We are so excited to be able to offer RFID-tagged generics for our hospital customers, and even more excited to be working with Sandoz on such a momentous launch,” said Kevin MacDonald, CEO and Co-Founder of Bluesight. “This is a pivotal moment for the industry and most importantly our hospital customers who can enjoy all the benefits of RFID-tagged medications, without the tagging labor. COVID-19 has made it all the more clear just how important it is to be able to keep an eye on each and every dose of medication in the hospital, and we are pleased to have joined forces with Sandoz on a real solution.”